ReviewhLife2025
Neutrophils: Key players in the metabolic syndrome puzzle.
Review in hLife, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metabolic syndrome (MetS) is a group of metabolic abnormalities associated with an increased risk of getting type 2 diabetes mellitus (T2DM) and cardiovascular disease (CVD). For many years, MetS has been viewed solely as a metabolic disease. In recent decades, MetS development has been associated with chronic inflammation related to nutrient excess, especially in the adipose tissues (AT). Metabolic stress, arising from the significant metabolic changes in MetS, is known to impact the balance of immune homeostasis. Although multiple immune cells have been investigated in this context, neutrophils, the first responder to inflammation, have only gained increased attention in recent years. Hence, this review aims to summarize the current evidence for the effects of MetS-induced systemic and AT-specific metabolic changes on neutrophils and their functions. We first provide an overview of the metabolic pathways used by neutrophils, with a specific focus on their recently discovered metabolic plasticity. This is followed by a discussion on the impact of MetS-induced alterations on the systemic metabolism and in the AT environment, how these changes may affect neutrophil effector functions, and the main mechanisms involved. Finally, we will examine the roles of neutrophils and their functions in T2DM and CVD that develop due to MetS. We will also provide perspectives on how a deeper understanding of the effects of systemic and site-specific metabolic changes in neutrophils and their effector functions could unlock the therapeutic potential of targeting neutrophils, as the arbiters of innate immunity in the context of MetS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.